Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.276.70 CHF
Change Today +2.80 / 1.02%
Volume 1.0M
ROG On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 11:43 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

George B. Abercrombie R.Ph., MBA

Former Chief Executive Officer of North American Pharmaceuticals Operations and President of North American Pharmaceuticals Operations, Roche Holding AG
AgeTotal Calculated CompensationThis person is connected to 30 board members in 4 different organizations across 10 different industries.

See Board Relationships
60$1,899,507

Background*

Mr. George B. Abercrombie, R.Ph., MBA, has been Senior Vice President of Corporate Partnerships & Commercial at Theravance Inc. since June 2014. Mr. Abercrombie has more than 30 years experience as a Business Leader in the pharmaceutical industry. He has substantial expertise in sales and marketing, executive sales management and business development. Mr. Abercrombie served as the Chief Executive Officer and President of Roche Laboratories, Inc. Mr. Abercrombie served ...

Read Full Background

Corporate Headquarters*

Konzern-Hauptsitz
Basel, Basel-Stadt 4070

Switzerland

Phone: 41 61 688 11 11
Fax: 41 61 691 93 91

Board Members Memberships*

Director
2010-Present
Director and Member of Audit Committee
2011-Present
Non-Executive Chairman, Member of Audit Committee, Member of Corporate Governance & Nominating Committee and Member of Compensation Committee
2013-Present
Director

Education*

MBA
Harvard Business School
BS
University Of North Carolina At Chapel Hill

Other Affiliations*

Annual Compensation*

Salary$219,167
Total Annual Compensation$219,167

Stock Options*

Restricted Stock Awards$293,200
All Other Compensation$500
Unexercisable Options100,000
Total Number of Options100,000

Total Compensation*

Total Annual Cash Compensation$389,667
Total Short Term Compensation$219,167
Other Long Term Compensation$293,700
Total Calculated Compensation$1,899,507
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.276.70 CHF +2.80

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$860.0K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$555.7K
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
874.0K GBP
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.